CDK4 and breast carcinoma: Regarding the use of CDK4/6 inhibitors in the treatment of HR-positive advanced breast cancer, multiple studies from the United States, the Netherlands, and Italy have shown that BMI has no significant association with overall survival (OS) and progression-free survival (PFS) [11–13].